These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 10519380)

  • 21. Association between polymorphism in p21(Waf1/Cip1) cyclin-dependent kinase inhibitor gene and human oral cancer.
    Ralhan R; Agarwal S; Mathur M; Wasylyk B; Srivastava A
    Clin Cancer Res; 2000 Jun; 6(6):2440-7. PubMed ID: 10873097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selection of cell death-deficient p53 mutants in Saccharomyces cerevisiae.
    Yacoubi-Hadj Amor I; Smaoui K; Belguith H; Djemal L; Dardouri M; Mokdad-Gargouri R; Gargouri A
    Yeast; 2009 Aug; 26(8):441-50. PubMed ID: 19579214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced latency but no increased brain tumor penetrance in mice with astrocyte specific expression of a human p53 mutant.
    Klein MA; Rüedi D; Nozaki M; Dell EW; Diserens AC; Seelentag W; Janzer RC; Aguzzi A; Hegi ME
    Oncogene; 2000 Nov; 19(47):5329-37. PubMed ID: 11103934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chromosomal instability and p53 inactivation are required for genesis of glioblastoma but not for colorectal cancer in patients with germline mismatch repair gene mutation.
    Leung SY; Yuen ST; Chan TL; Chan AS; Ho JW; Kwan K; Fan YW; Hung KN; Chung LP; Wyllie AH
    Oncogene; 2000 Aug; 19(35):4079-83. PubMed ID: 10962567
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status.
    Bartussek C; Naumann U; Weller M
    Exp Cell Res; 1999 Dec; 253(2):432-9. PubMed ID: 10585266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of survivin and p53 in human oral cancer: correlation with clinicopathologic findings.
    Khan Z; Tiwari RP; Mulherkar R; Sah NK; Prasad GB; Shrivastava BR; Bisen PS
    Head Neck; 2009 Aug; 31(8):1039-48. PubMed ID: 19340865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
    Baumbusch LO; Myhre S; Langerød A; Bergamaschi A; Geisler SB; Lønning PE; Deppert W; Dornreiter I; Børresen-Dale AL
    Mol Cancer; 2006 Oct; 5():47. PubMed ID: 17054774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An engineered four-stranded coiled coil substitutes for the tetramerization domain of wild-type p53 and alleviates transdominant inhibition by tumor-derived p53 mutants.
    Waterman MJ; Waterman JL; Halazonetis TD
    Cancer Res; 1996 Jan; 56(1):158-63. PubMed ID: 8548757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longitudinal study of TP53 mutations in eight patients with potentially malignant oral mucosal disorders.
    Ogmundsdóttir HM; Hilmarsdóttir H; Björnsson J; Holbrook WP
    J Oral Pathol Med; 2009 Oct; 38(9):716-21. PubMed ID: 19473449
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.
    Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H
    Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
    Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
    J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
    Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Functional restoration of tumor suppressor p53 alters susceptibility of glioblastoma cells to irradiation--analysis using a cell line containing a temperature-sensitive mutant].
    Tsuchiya K
    Hokkaido Igaku Zasshi; 2000 Jul; 75(4):265-74. PubMed ID: 10976406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.
    Kato S; Han SY; Liu W; Otsuka K; Shibata H; Kanamaru R; Ishioka C
    Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8424-9. PubMed ID: 12826609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spectrum of p53 mutations in biopsies from breast cancer patients selected for preoperative chemotherapy analysed by the functional yeast assay to predict therapeutic response.
    Deissler H; Kafka A; Schuster E; Sauer G; Kreienberg R; Zeillinger R
    Oncol Rep; 2004 Jun; 11(6):1281-6. PubMed ID: 15138567
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation among pathology, genotype, and patient outcomes in glioblastoma.
    Homma T; Fukushima T; Vaccarella S; Yonekawa Y; Di Patre PL; Franceschi S; Ohgaki H
    J Neuropathol Exp Neurol; 2006 Sep; 65(9):846-54. PubMed ID: 16957578
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transforming activity of mutant human p53 alleles.
    Slingerland JM; Benchimol S
    J Cell Physiol; 1991 Sep; 148(3):391-5. PubMed ID: 1918170
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract.
    Waridel F; Estreicher A; Bron L; Flaman JM; Fontolliet C; Monnier P; Frebourg T; Iggo R
    Oncogene; 1997 Jan; 14(2):163-9. PubMed ID: 9010218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional analysis of p53 tumor suppressor in yeast.
    Smardová J; Smarda J; Koptíková J
    Differentiation; 2005 Jul; 73(6):261-77. PubMed ID: 16138827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient with multiple primary carcinomas including 4 separate oral cancers: study of p53 mutations and their implications for management.
    Fukuda M; Nakatsuka T; Kusama K; Sakashita H
    J Oral Maxillofac Surg; 2006 Nov; 64(11):1672-9. PubMed ID: 17052595
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.